Profile data is unavailable for this security.
About the company
Sakar Healthcare Limited is an India-based pharmaceutical company. The Company is engaged in manufacturing of pharmaceutical products providing liquid orals, cephalosporin tablets, capsules, dry powder syrup, dry powder injections, liquid injectables (SVP) in ampoules and vials & lyophilized injections. The Company's oncology products include oral solid dosage (tablet & capsule), liquid injection, lyophilized injection, active pharmaceutical ingredient (API), CDMO products and CRAMs. It has a presence across the regions of Africa (Anglo & Francophone), SEASIA, CIS, Latin & Central America and in Europe. It operates in over 50 countries globally and has approximately 292 registered products. It exports to Southeast Asia, Asia, Africa-Anglo & Francophone, MENA, America, covering around 38 countries with more than 250 brands registered.
- Revenue in INR (TTM)2.31bn
- Net income in INR252.21m
- Incorporated2004
- Employees342.00
- LocationSakar Healthcare Ltd406,Silver Oaks Comm. Complex,Opp. Arun Society, PaldiAHMEDABAD 380007IndiaIND
- Phone+91 7 926584655
- Fax+91 2 717251621
- Websitehttps://www.sakarhealthcare.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accent Microcell Ltd | 2.78bn | 346.64m | 7.96bn | 192.00 | 21.78 | 3.19 | 20.46 | 2.86 | 15.24 | 15.24 | 122.20 | 104.07 | 1.12 | 4.14 | 5.32 | 14,474,330.00 | 13.99 | -- | 15.95 | -- | 39.96 | -- | 12.47 | -- | 3.01 | 76.48 | 0.0046 | -- | 7.77 | -- | 9.60 | -- | -- | -- |
| Wanbury Ltd | 6.58bn | 646.86m | 8.56bn | 1.38k | 12.80 | -- | 10.81 | 1.30 | 19.13 | 19.13 | 194.16 | -- | -- | -- | -- | 4,758,967.00 | -- | 8.87 | -- | 101.40 | 55.07 | 41.82 | 9.84 | 5.62 | -- | 2.97 | -- | -- | 4.15 | 10.29 | -45.44 | -13.88 | 44.32 | -- |
| Venus Remedies Ltd | 7.00bn | 762.95m | 9.03bn | 1.30k | 11.83 | -- | 9.04 | 1.29 | 57.10 | 57.10 | 523.77 | -- | -- | -- | -- | 5,391,957.00 | -- | 6.67 | -- | 8.08 | 47.02 | 37.62 | 10.90 | 6.87 | -- | 1,849.19 | -- | -- | 7.72 | 13.81 | 59.05 | -- | 18.36 | -- |
| Bajaj Healthcare Ltd | 6.12bn | 523.16m | 10.15bn | 904.00 | 19.90 | -- | 12.72 | 1.66 | 16.15 | 15.36 | 188.83 | -- | -- | -- | -- | 6,774,850.00 | -- | 7.07 | -- | 13.07 | 46.31 | 37.17 | 8.54 | 8.22 | -- | 2.92 | -- | 5.83 | 14.61 | 5.76 | 399.64 | 11.21 | -12.65 | -- |
| Beta Drugs Ltd | -100.00bn | -100.00bn | 10.68bn | 399.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 15.08 | -- | 21.53 | -- | 40.30 | -- | 12.72 | -- | -- | -- | 0.00 | 22.54 | 31.89 | 28.96 | 37.92 | 19.23 | -- |
| IND Swift Laboratories Ltd | 9.64bn | 2.75bn | 10.94bn | 1.25k | 3.30 | -- | 3.40 | 1.14 | 38.28 | 38.28 | 122.91 | -- | -- | -- | -- | 7,738,014.00 | -- | 8.65 | -- | 10.59 | 51.55 | 40.96 | 28.56 | 14.35 | -- | -3.35 | -- | 0.00 | -56.15 | -6.35 | -40.50 | -- | 41.97 | -- |
| Syncom Formulations (India) Ltd | 5.03bn | 689.58m | 11.40bn | 554.00 | 15.55 | -- | 15.35 | 2.27 | 0.78 | 0.78 | 5.58 | -- | -- | -- | -- | 9,072,854.00 | -- | 8.56 | -- | 11.58 | 40.05 | 34.81 | 13.72 | 10.15 | -- | 75.71 | -- | -- | 76.55 | 17.74 | 95.28 | 28.24 | 41.62 | -- |
| Jagsonpal Pharmaceuticals Ltd | 2.82bn | 409.03m | 11.41bn | 1.40k | 28.10 | -- | 22.67 | 4.05 | 6.07 | 6.07 | 41.76 | -- | -- | -- | -- | 2,012,738.00 | -- | 14.71 | -- | 17.26 | 63.66 | 60.59 | 14.53 | 12.54 | -- | 44.64 | -- | 39.88 | 28.76 | 11.13 | 146.45 | 47.72 | -28.44 | 65.72 |
| Sakar Healthcare Ltd | 2.31bn | 252.21m | 11.60bn | 342.00 | 45.53 | -- | 24.01 | 5.03 | 11.45 | 11.45 | 104.95 | -- | -- | -- | -- | 6,750,901.00 | -- | 4.73 | -- | 5.64 | 52.54 | 45.55 | 10.92 | 9.87 | -- | 3.66 | -- | -- | 15.80 | 16.44 | 49.96 | 12.71 | 19.34 | -- |
| Lincoln Pharmaceuticals Ltd | 6.52bn | 878.34m | 12.39bn | 1.85k | 14.10 | -- | 12.16 | 1.90 | 43.86 | 43.86 | 325.55 | -- | -- | -- | -- | 3,518,272.00 | -- | 13.22 | -- | 15.46 | 53.64 | 50.82 | 13.47 | 14.56 | -- | 77.35 | -- | 3.32 | 7.35 | 10.03 | -11.74 | 9.87 | 20.13 | -- |
| Hester Biosciences Ltd | 3.14bn | 409.47m | 12.85bn | 562.00 | 40.07 | -- | 21.55 | 4.09 | 37.69 | 37.69 | 277.25 | -- | -- | -- | -- | 5,594,555.00 | -- | 5.39 | -- | 6.72 | 73.52 | 64.87 | 13.51 | 11.44 | -- | 9.65 | -- | 23.77 | 2.15 | 11.16 | 45.52 | -1.18 | -22.47 | 1.18 |
| Ngl Fine Chem Ltd | 4.47bn | 353.73m | 14.43bn | 456.00 | 40.80 | -- | 27.12 | 3.23 | 57.26 | 57.26 | 723.35 | -- | -- | -- | -- | 9,799,871.00 | -- | 13.34 | -- | 17.44 | 51.62 | 41.63 | 7.92 | 12.15 | -- | 9.06 | -- | 2.85 | 8.73 | 19.41 | -48.87 | 20.44 | 53.91 | 0.00 |
Data as of Mar 05 2026. Currency figures normalised to Sakar Healthcare Ltd's reporting currency: Indian Rupee INR
6.83%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| HBM Partners AG (Investment Management)as of 31 Dec 2025 | 1.50m | 6.83% |
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
